Exelixis, Inc. $EXEL Shares Purchased by Vestcor Inc

Vestcor Inc lifted its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 9.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 205,795 shares of the biotechnology company’s stock after acquiring an additional 18,529 shares during the quarter. Vestcor Inc owned 0.08% of Exelixis worth $8,499,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. AQR Capital Management LLC increased its stake in shares of Exelixis by 10.3% in the second quarter. AQR Capital Management LLC now owns 7,606,079 shares of the biotechnology company’s stock valued at $335,238,000 after purchasing an additional 712,190 shares during the period. Geode Capital Management LLC raised its holdings in shares of Exelixis by 0.4% in the 2nd quarter. Geode Capital Management LLC now owns 7,445,469 shares of the biotechnology company’s stock worth $328,196,000 after purchasing an additional 28,289 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in shares of Exelixis by 42.9% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 5,262,643 shares of the biotechnology company’s stock worth $231,951,000 after acquiring an additional 1,580,567 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Exelixis by 11.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 4,180,912 shares of the biotechnology company’s stock worth $172,658,000 after purchasing an additional 419,596 shares in the last quarter. Finally, Assetmark Inc. raised its stake in Exelixis by 1,230.8% during the 3rd quarter. Assetmark Inc. now owns 3,195,971 shares of the biotechnology company’s stock valued at $131,994,000 after purchasing an additional 2,955,813 shares during the period. 85.27% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Exelixis

In other news, Director Bob Oliver sold 30,250 shares of Exelixis stock in a transaction on Friday, February 13th. The stock was sold at an average price of $43.81, for a total value of $1,325,252.50. Following the transaction, the director owned 21,120 shares in the company, valued at approximately $925,267.20. This trade represents a 58.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Christopher J. Senner sold 34,278 shares of Exelixis stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $43.00, for a total value of $1,473,954.00. Following the completion of the transaction, the chief financial officer owned 1,042,579 shares in the company, valued at approximately $44,830,897. This represents a 3.18% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 362,849 shares of company stock valued at $15,917,463. 2.85% of the stock is currently owned by insiders.

Exelixis Stock Performance

Shares of NASDAQ:EXEL opened at $42.37 on Tuesday. The company has a market capitalization of $11.00 billion, a P/E ratio of 15.30, a price-to-earnings-growth ratio of 0.93 and a beta of 0.41. Exelixis, Inc. has a 52-week low of $32.38 and a 52-week high of $49.62. The company has a 50-day simple moving average of $43.51 and a 200 day simple moving average of $41.62.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.20. The company had revenue of $598.66 million during the quarter, compared to analysts’ expectations of $609.17 million. Exelixis had a net margin of 33.73% and a return on equity of 36.29%. Exelixis’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.55 earnings per share. As a group, equities analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on EXEL shares. Citigroup lowered shares of Exelixis from a “market outperform” rating to an “underperform” rating in a research report on Monday, January 5th. Morgan Stanley increased their price objective on Exelixis from $48.00 to $49.00 and gave the company an “equal weight” rating in a research report on Monday, February 2nd. UBS Group set a $41.00 price target on Exelixis in a research note on Monday, January 5th. Zacks Research downgraded Exelixis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, March 5th. Finally, Barclays lifted their target price on shares of Exelixis from $41.00 to $44.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 4th. Ten analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $46.94.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.